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Introduction
The endometrium represents a unique kind of tissue
with immunomodulating activity that enables the
accumulation of active cytotoxic cells during the
implantation window. In order to evaluate more close-
ly the dynamic changes that take place during the men-
strual cycle phases, the menstrual cycle has been fur-
ther divided into six sub-phases: early-, mid-, and late-
proliferative, and early-, mid-, and late- secretory
[1,2]. The cyclic alterations of the immunomodulating
factor expressions such as interleukins (IL-1, IL-11,
IL-13, IL-15, IL-18) leukemia inhibitory factor (LIF),
mRNA transcripts encoding regulated upon activation
normal T-cell-expressed and -secreted (RANTES),
Fas, Fas-L, tumor necrosis factor-alpha (TNF-alpha),
HOXA10 and others have been observed in the
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Abstract: RCAS1 expression is related to the regulation of activated immune cells and to connective tissue remodeling
within the endometrium. DFF45 seems to play an important role in the apoptotic process, most likely by acting through the
regulation of DNA fragmentation. Its expression changes within the endometrium seem to be related to the resistance of
endometrial cells to apoptosis. The aim of the present study was to evaluate RCAS1 and DFF45 endometrial expressions
during ovulation and the implantation period.  RCAS1 and DFF45 expression was assessed by the Western-blot method in
endometrial tissue samples obtained from 20 patients. The tissue samples were classified according to the menstrual cycle
phases in which they were collected, with a division into three phases: late proliferative, early secretory, and mid-secretory.
The lowest level of RCAS1 and the highest level of DFF45 endometrial expression was found during the early secretory
cycle phase. Statistically significantly higher RCAS1 and statistically significantly lower DFF45 endometrial expression
was identified in the endometrium during the late proliferative as compared to the early secretory cycle phase. Moreover,
statistically significantly higher RCAS1 and statistically significantly lower DFF45 expression was found in the endometri-
um during the mid-secretory as compared to the early secretory cycle phase. The preparation for implantation process in the
endometrium is preceded by dynamic changes in endometrial ECM and results from the proper interaction between endome-
trial and immune cells. The course of this process is conditioned by the immunomodulating activity of endometrial cells and
their resistance to immune-mediated apoptosis. These dynamic changes are closely related to RCAS1 and DFF45 expres-
sion alterations. 
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endometrium [3-18]. Recently, RCAS1 (receptor-
binding cancer antigen expressed on SiSo cells) pro-
tein has been shown to participate in the regulation of
immune cell activity in the endometrium [19-24].
RCAS1 has been observed as a factor responsible for
tumor escape from host immunological surveillance
[19,20,26]. RCAS1 may induce apoptosis of cytotoxic
lymphocytes and mainly leads to strong suppression of
lymphocyte growth [19,25,26].  Moreover, it has been
suggested that RCAS1 also induces connective tissue
remodeling [25,27]. A dispersion of extracellular
matrix (ECM) during the mid-secretory phase of the
cycle has been found to be crucial for ovum implanta-
tion [28]. Besides the endometrial immunomodulating
activity, its proper function is preserved by the protec-
tion of endometrial cells from immune-mediated apop-
tosis through the disturbance of apoptotic signal trans-
duction. This endometrial ability has been named
resistance to immune-mediated apoptosis and seems to
be linked with DNA fragmentation factor (DFF)
expression changes [29]. DFF is composed of a 40
kDa protein DFF40, with a nuclease activity, and a 45
kDa protein inhibitory sub-unit DFF45 [30]. DFF45
seems to play an important role in the onset of the
apoptotic process, most likely by acting through the
regulation of DNA fragmentation [30-33]. The aim of
the present study was to evaluate RCAS1 and DFF45
endometrial expressions with respect to the menstrual
cycle phase (late proliferative, early secretory, and
mid-secretory) as these factors have not been estimat-
ed simultaneously in the endometrium during ovula-
tion and the implantation period.  
Materials and methods
Tissue samples. Human endometrial tissues were obtained from
20 non-menopausal fertile women, aged 20-47 years. These
patients had all undergone hysterectomies due to benign gynecol-
ogical indication (leiomyomas). No patient included in our study
received any hormonal treatment. The surgical procedure was per-
formed in the Gynecology and Obstetrics Department, headed by
Professor Antoni Basta, of the Jagiellonian University in Krakow,
Poland. Tissue samples were classified according to the menstrual
cycle phase in which they were collected, with division into the
three phases: late proliferative (9 cases), early secretory (5 cases),
and mid-secretory (6 cases).  
Preparation of tissue extracts and Western blotting. The speci-
mens were mixed with a complete proteinase inhibitor cocktail
(Roche, Germany) and homogenized in an ice-bath in a glass-glass
Potter-Elvejhem homogenizer. The resulting suspensions were
mixed with equal volumes of SDS sample lysis buffer (4% SDS,
20% glycerol, 125 mM Tris-HCl pH=6.8) and boiled in a water
bath for 5 minutes. The chilled samples were then centrifuged at
16,000 g for 15 min at room temperature. The collected super-
natants were used for further analysis. Total protein content in the
obtained supernatants was measured using a BCA assay kit, and
different sample volumes (usually in the range of 2-10 μl), equiv-
alent to 50 μg of total protein were then loaded on SDS-PAGE tris-
tricine peptide-separating gels. A pre-stained broad range molecu-
lar weight proteins standard (Bio Rad, USA) was used in the gel
marker lane. Following electrophoresis, the gels were electro-
transferred on Immobilon-P polyvinylidene difluoride (PVDF)
0.45 μm membrane (Millipore, USA) in the buffer containing 10
mM 3-[cyclohexyloamino]-1-propanesulfonic acid (CAPS)
pH=11, supplemented with 10% methanol. The obtained mem-
brane blots were blocked overnight by gentle agitation in 5%
bovine albumin in TST buffer (0.01 M Tris-HCl, pH=7.4, 0.9%
NaCl), 0.5% Tween-20). All described procedures were performed
at room temperature. The albumin solution was discarded and the
membranes were then agitated for 2 hrs in TST with the mouse
monoclonal anti-RCAS1 IgM-class antibody, 1: 4000 dilution
(Medical and Biological Laboratories, Japan) and, in the second
step, monoclonal antibody against DFF-45 (Abcam, USA). The
membranes were then subjected to 4 cycles of washings in TST, 5
min each, and immersed for agitation in the 1: 2 000 dilution of
SIGMA biotinylated anti-mouse IgM μ-chain specific antibodies
for a 2-hour period. After 4 cycles of washings, the membranes
were treated for an additional 2 hours in 1: 2 000 dilution of ExtrA-
vidin alkaline phosphatase conjugate (SIGMA, USA), and finally
washed 2 times in TST and 2 times in TST without Tween-20.
Color reaction was developed with the use of Fast Red TR/Naph-
tol AS-MX tablet set (SIGMA, USA). A sufficient band intensity
was obtained, usually after a 5 min period of developing. The
obtained immunoblots were then rinsed with distilled water and
air-dried. The RCAS1 antigen was identified as a 32 kDa band,
DFF45 as a 45 kDa band, and β-actin represented a 42 kDa band
[29,30,34]. 
Computer aided image analysis. Fluor-S MultiImager (BioRad,
USA) was used to scan immunoblotted membranes and a Quanti-
tyOne software (BioRad, USA) was used to quantitate band inten-
sities. All calculations were performed on RCAS1 antigen band
having a molecular mass of about 32 kDa, DFF-45 of 45 kDa. The
intensities of this band were expressed in arbitrary relative units,
and one unit (U) was defined as band intensity produced in the ref-
erence sample. This reference sample was randomly chosen, but
was strictly the same on all blots and was applied in the same
amount each time. The typical procedure of RCAS1 and DFF45
quantitation was as follows: scanned immunoblot membrane con-
tained one lane of molecular mass standards, while one lane of sam-
ple was used as a reference to calibrate RCAS1 and DFF45 amounts
and 12 lanes containing unknown samples. The location of 32 kDa
RCAS1 and 45kDa bands in reference and unknown lanes were
identified according to the lane containing molecular mass standard.
The bands' intensities in reference and unknown lanes were then cal-
culated and expressed in pixel number units. These units were divid-
ed by pixel number of reference lane band which resulted in relative-
intensity units "U". The resulting intensity of reference lane band
was always 1.00 U while the intensities of bands from 12 unknown
sample lanes on the same membrane changed according to RCAS1
and DFF45 levels (e.g., if RCAS1 amount in a given sample was 2
times higher than this in the reference sample, the result was 2.00 U.
If the RCAS1 amount was 2 times lower, then the result was 0.50 U).
As mentioned earlier, because all immunoblots contained the same
RCAS1 and DFF45 quantity standard and all lanes were loaded with
the same amount of total protein (50 μg), the determined values were
highly repetitive and independent of the experiment conditions. The
results consistently show a relative amount of RCAS1 32 kD antigen
and DFF45 of 45 kDa and beta-Actin 42 kDa in 50 μg of total sam-
ple protein [29,30,34].
Quantity control. Using the Western-blot method and monoclon-
al anti-β-Actine mouse antibody, the relative quantity of β-Actine
was estimated as a control [34]. 
Statistics. The statistical significance between the groups was
determined by the analysis of variance (ANOVA) test. Post-hoc
Fisher test was used as applicable. 
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Ethical issues. The patient's consent was obtained in all cases.
Prior to the study, the approval of the research program by the
Jagiellonian University Ethical Committee was also obtained
(KBET/89/B/2005).
Results
The amount of β-Actin level in all the groups of exam-
ined endometrial tissue was found to be identical; this
indicates that the loading of protein was equal in all the
examined samples and allows the performance of a
comparative study of RCAS1 and DFF45 expression
between the examined groups.
The lowest level of RCAS1 and the highest level of
DFF45 endometrial expression was found during the
early secretory cycle phase. Statistically significantly
higher RCAS1 and statistically significantly lower
DFF45 endometrial expression was identified in the
endometrium during the late proliferative as compared
to the early secretory cycle phase. Moreover, statisti-
cally significantly higher RCAS1 and statistically sig-
159RCAS1 and DFF-45 endometrial expression 
Fig. 1. Presents a comparison of
RCAS1 endometrial expression changes
between the late proliferative (LP),
early secretory (ES), and mid-secretory
(MS) cycle phases. Each box repre-
sents the 25-75% range of data. The
median () was presented for each
group. Statistically significant differ-
ences were observed in RCAS1 rela-
tive amount: aLP versus ES (p=0.04);
bES versus MS (p<0.01).
Fig. 2. Presents a comparison of
DFF45 endometrial expression changes
between the late proliferative (LP),
early secretory (ES), and mid-secretory
(MS) cycle phases. Each box repre-
sents the 25-75% range of data. The
median () was presented for each
group. Statistically significant differ-
ences were observed in the DFF45 rel-
ative amount: aLP versus ES
(p<0.001); bES versus MS (p<0.001).
nificantly lower DFF45 expression was found in the
endometrium during the mid-secretory as compared to
the early secretory cycle phase.
Discussion
Dynamic changes in DFF45 and RCAS1 expression
were observed in the endometrium during the late prolif-
erative, early secretory and mid-secretory cycle phases.
To our knowledge, this is the first investigation to focus
on RCAS1 and DFF45 expression in the endometrium
during the periovulatory period. Until now, a simultane-
ous analysis of RCAS1 and DFF45 expressions had only
been performed on nasal polyps [35].
Changes in apoptotic levels corresponding to the
menstrual cycle phases have been observed in the
endometrium. Apoptosis is more prominent during the
secretory cycle phase than the proliferative, and its
level increases insignificantly during menstruation
[36]. The disturbance of apoptosis leads to either a dis-
abling of apoptotic signal transduction or to an inabil-
ity to receive such a signal [37]. Watanabe et al. have
therefore suggested that endometrial cell apoptosis
may not depend on the expression of Bcl-2 level and
the Fas expression [37]. The initiation of apoptosis
seems result from the activity of various factors. In the
final stage of this process, DNA fragmentation related
to the level of DNA-nuclease (DFF40) activity can be
observed [30-33]. The activation of this enzyme is
processed by the fragmentation of DFF45/DFF40
complex by caspase-3 [30]. Since DFF45 is able to
interact with this nuclease as a molecular chaperone
and ensures its correct folding, it was shown to be nec-
essary for generating functional DFF40 nuclease
[31,38]. It has also been demonstrated that DFF45-
deficient thymocytes were more resistant to pro-
grammed cell death [32]. Moreover, in esophageal and
colon carcinoma cells characterized by an impairment
of apoptosis, a decrease of DFF45 level has been
observed [33]. Its expression changes within the
endometrium seem to be related to the resistance of
endometrial cells to immune-mediated apoptosis. In
our recent study, an increase of DFF45 expression was
found in the secretory cycle phase in comparison to the
proliferative [29]. As in this study the more detailed
division of the cycle into the six sub-phases was not
considered, the differences between the periovulatory
and implantation period were not able to be shown.
The dispersion of ECM begins during the implantation
window [28,39-41]. This is the process that is most
likely related to the changes in the resistance to apop-
tosis level and that seems to be crucial for ovum
implantation. Nevertheless, the increase in the level of
endometrial cell resistance to apoptosis appears earli-
er, during ovulation, and alters during the early secre-
tory cycle phase. This finding was confirmed in the
present study by the changes in DFF45 level.  More-
over, Tabibzadeh [28] has stated that the balance
between the grade of TGF-beta (transforming growth
factor - beta) activity and LEFT protein expression is
essential for endometrial ECM status [42-44]. LEFTY
might affect matrix metalloproteinases (MMP)
endometrial activity [44], while MMP is responsible
for endometrial ECM disintegration [45]. Further-
more, Sonoda has shown the association between
RCAS1 expression and MMP-1 expression in the
tumor micro-environment of the uterine cervix [27].
RCAS1 seems also to be responsible for tissue remod-
eling [20,25,27]. The status of endometrial ECM is
regulated as well by the infiltrating immune cells
[46,47]. Immune cells constitute 7% of all endometri-
al cell population during the proliferative menstrual
cycle phase; during the secretory cycle phase, their
percentage increases to 30 [48]. The increase in
immune cell infiltration starts during the late prolifer-
ative cycle phase and peaks during the mid-secretory
cycle phase. Immune cell status depends on the con-
centration of immunomodulating factors derived from
endometrial cells, including RCAS1 [49]. So far the
evaluated results in RCAS1 expression level in the
endometrium with respect to menstrual cycle phases
have been controversial. On the one hand, it has been
demonstrated that RCAS1 expression level does not
differ with respect to menstrual cycle phases
[21,25,50]. On the other hand, it has been observed
that RCAS1 expression during the secretory cycle
phase was statistically significantly higher than during
the proliferative phase [22,23]. These obtained various
results in RCAS1 expression could derive from the
dynamic changes in RCAS1 expression found between
late proliferative, early secretory, and mid-secretory
cycle phases. 
The preparation for the implantation process in the
endometrium is preceded by dynamic changes in
endometrial ECM and results from the proper interac-
tion between endometrial and immune cells. The
course of this process is conditioned by the
immunomodulating activity of endometrial cells and
their resistance to immune-mediated apoptosis. These
dynamic changes are closely related to those observed
in the current study of RCAS1 and DFF45 expression
alterations. 
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